CYP39A1 polymorphism is associated with toxicity during intensive induction chemotherapy in patients with advanced head and neck cancer.

Melchardt, Thomas

CYP39A1 polymorphism is associated with toxicity during intensive induction chemotherapy in patients with advanced head and neck cancer. [electronic resource] - BMC cancer Oct 2015 - 725 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

1471-2407

10.1186/s12885-015-1776-x doi


Adult
Aged
Cisplatin--administration & dosage
Disease-Free Survival
Docetaxel
Female
Fluorouracil--administration & dosage
Genotype
Head and Neck Neoplasms--drug therapy
Humans
Induction Chemotherapy--adverse effects
Male
Middle Aged
Polymorphism, Genetic
Polymorphism, Single Nucleotide
Steroid Hydroxylases--genetics
Taxoids--administration & dosage